New Results From KARDIA-2 Phase 2 Study Presented at the 2024 American College of Cardiology Annual Scientific Session

07 Apr, 2024 New Results From KARDIA-2 Phase 2 Study Presented at the 2024 American College of Cardiology Annual Scientific Session

Results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension, when added to standard of care antihypertensive medications, were presented at the 2024 American College of Cardiology (ACC) Annual Scientific Session.

Bakris, et al. “Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension – Primary Results From The Phase 2 KARDIA-2 Study”